Lung Cancer

Certain NSCLC Patients More Likely to Respond to Immunotherapy, Study Finds

December 2nd 2020, 9:00pm


A recent study investigated what makes some non-small cell lung cancer patients with a type of human leukocyte antigen (HLA) called B44 are more likely than others to respond to immunotherapy.

The Importance of Cancer Clinical Trials, Even in a Pandemic

November 25th 2020, 5:00pm


Physicians and patient advocates alike are working to spread the message that it is safe to continue on the course of cancer care and participate in clinical trials during COVID-19.

Joanna Thompson Outlines How Highlands Oncology Group Screens for Lung Cancer

November 22nd 2020, 3:30pm


The Highlands Oncology Group partners with primary care providers to identify patients at high risk of lung cancer so the specialists can do a more in-depth screening, explained Joanna Thompson, multidisciplinary program manager, Highlands Oncology Group.

First-Line Lorlatinib Improves PFS in ALK-Positive NSCLC

November 20th 2020, 6:45pm


Early treatment with lorlatinib led to improved progression-free survival in ALK-positive NSCLC patients compared with crizotinib treatment, a study published in the New England Journal of Medicine found.

Multidisciplinary Lung Cancer Clinic Saves Patients, System Costs

November 18th 2020, 4:00pm


Multidisciplinary lung cancer clinics might help patients and the system save on treatment costs while improving patient experiences, according to an abstract presented at CHEST 2020.

Contributor: Links Between COVID-19 Comorbidities, Mortality Detailed in FAIR Health Study

November 11th 2020, 1:30pm


In patients under age 70, lung cancer conferred the highest risk of death from coronavirus disease 2019 (COVID-19).

Lung Cancer Screening Criteria Miss Young, High-Risk Black Smokers

November 9th 2020, 4:30pm


Current lung cancer screening guidelines do not identify high-risk young, African American smokers, an abstract presented at CHEST 2020 found.

Can Emphasis on Education Increase Lung Cancer Screenings?

November 4th 2020, 9:30pm


Abstracts presented at CHEST 2020 explored possible reasons for low lung cancer screening rates and suggested solutions.

Libtayo Accepted for FDA Priority Review in NSCLC With PD-L1 Expression

November 3rd 2020, 9:00pm


Regeneron’s PD-1 inhibitor Libtayo was accepted for priority FDA review for the treatment of first-line locally advanced or metastatic non–small cell lung cancer (NSCLC) with PD-L1 expression of at least 50%.

Lung Cancer in Women: More Risk, Less Attention

October 31st 2020, 2:00pm


Current screening criteria in the United States identify fewer women than men who will get lung cancer, creating a perfect storm for what experts during a session at the CHEST Annual Meeting deemed an “invisible epidemic.”